Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Hyaluronic Acid
Hospital Authority, Hong Kong
Shoulder Pain
1 trial -
Hydrochloride anlotinib
Zhongnan Hospital
Uterine Cervical Neoplasms
1 trial -
Hydrochlorothiazide, Captopril, Nitrendipine, Aspirin
The First People's Hospital of Lianyungang
Hypertension
1 trial -
Hydrogen Peroxide 3 % Topical Solution
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Warts
1 trial -
Hydrolysed Collagen (PROTÉGEN Plus)
Hospital Authority, Hong Kong
Fragility Fracture
1 trial -
Hydromorphone combined with ropivacaine
Second Hospital of Jilin University
Inguinal Hernia
1 trial -
Hypervision proton surgery
Hospital Authority, Hong Kong
Non-Small Cell Lung Cancer
1 trial -
Hypofraction radiation
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Nasopharyngeal Carcinoma
1 trial -
Hypofractionated Radiation Therapy
The First People's Hospital of Lianyungang
Breast Cancer
1 trial -
Hypofractionated radiotherapy
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Lung Cancer
1 trial -
IORT
The First People's Hospital of Lianyungang
Laryngeal Neoplasms
1 trial -
IPT plus HD-tDCS
The First People's Hospital of Lianyungang
Depressive Disorder
1 trial -
Immediate CEUS
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Liver Cancer
1 trial -
Immunohistochemistry or genetic test
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Glioma
1 trial -
Immunosuppressive therapy
Xiyuan Hospital of China Academy of Chinese Medical Sciences
In-stent Restenosis Lesion
1 trial -
Indometacin suppository
The First People's Hospital of Lianyungang
Pancreatitis, Chronic
1 trial -
Indomethacin and Ibuprofen
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Ductus Arteriosus, Patent
1 trial -
Induction therapy-2 cycles of VPX (Teniposide, PD-1 monoclonal antibody plus Selinixor)
The First People's Hospital of Lianyungang
Primary Central Nervous System Lymphoma (PCNSL)
1 trial -
Induction therapy-3 cycles of BvC (Brentuximab vedotin plus Chidamide)
The First People's Hospital of Lianyungang
CD30+ Peripheral T-cell Lymphoma
1 trial -
Induction therapy-3 cycles of BvC (Brentuximab vedotin plus Chidamide)
Hospital Authority, Hong Kong
CD30+ Peripheral T-cell Lymphoma
1 trial -
Induction therapy-Pro regimen
The First People's Hospital of Lianyungang
Diffuse Large B-Cell Lymphoma
1 trial -
Influence of propofol sedation on memory consolidation and 'working memory'
The First People's Hospital of Lianyungang
Memory Impairment
1 trial -
Infrared thermography
The First People's Hospital of Lianyungang
Chronic Obstructive Pulmonary Disease
1 trial -
Inhaled Placebo
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Ventilator-Associated Pneumonia (VAP)
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources